{"id":62870,"date":"2026-03-31T10:02:27","date_gmt":"2026-03-31T08:02:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/"},"modified":"2026-03-31T10:02:27","modified_gmt":"2026-03-31T08:02:27","slug":"palliser-capital-publishes-value-enhancement-plan-for-ajinomoto","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/","title":{"rendered":"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Value Enhancement Plan addresses key drivers of Ajinomoto\u2019s valuation disconnect and sets out a clear, actionable pathway to unlock over 70% upside for shareholders<\/i><\/li>\n<li>\n<i>Presentation highlights Ajinomoto as \u201cThe Most Under\u2011Monetised AI Infrastructure Monopoly,\u201d underscoring significant under-appreciated pricing upside of Ajinomoto Build-up Film (\u201cABF\u201d)<\/i><\/li>\n<\/ul>\n<p>LONDON&#8211;(BUSINESS WIRE)&#8211;Palliser Capital (\u201cPalliser\u201d), a top 25 shareholder of Ajinomoto Co., Inc. (\u201cAjinomoto\u201d or the \u201cCompany\u201d), today published a comprehensive presentation outlining the opportunities available to unlock significant long\u2011term value at Ajinomoto.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/1\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/1\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/1\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/21\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761326\/5\/Palliser-logo-blue_4x.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761326\/22\/Palliser-logo-blue_4x.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761326\/5\/Palliser-logo-blue_4x.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761326\/21\/Palliser-logo-blue_4x.jpg\"><\/a><\/p>\n<p>\nTo promote market transparency and respond to growing interest from shareholders and other stakeholders, Palliser has made public a detailed presentation titled \u201cMaximising the Value of Ajinomoto \u2013 The Most Under\u2011Monetised AI Infrastructure Monopoly.\u201d The presentation sets out Palliser\u2019s assessment of Ajinomoto\u2019s unique strategic positioning within the global AI supply chain, the structural drivers of its persistent undervaluation, and the tangible steps required to drive a material re\u2011rating of the Company\u2019s equity.<\/p>\n<p>\nDespite owning one of the most critical materials technologies underpinning global AI infrastructure, Ajinomoto currently trades at a significant valuation discount to its ABF substrate customers. Resolving the drivers of this valuation disconnect could unlock well over 70% upside to the current share price and support sustained long\u2011term value creation in the interests of all stakeholders. The Ajinomoto Value Enhancement Plan outlines three highly actionable initiatives:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Establish the Functional Materials business as a standalone reporting segment<\/b>, materially improving disclosure and transparency to enable investors to properly assess the competitive moat, growth trajectory, and intrinsic value of the ABF franchise;<\/li>\n<li>\n<b>Increase ABF pricing by over 30%<\/b>, capturing the economics of ABF\u2019s monopoly\u2011grade, mission\u2011critical role in global AI infrastructure while having a negligible impact on customer economics; and<\/li>\n<li>\n<b>Restructure the Frozen Food business to achieve a ROIC above 8%<\/b>, in line with Japanese and U.S. peers, through portfolio rationalisation, pricing and mix optimisation, and improved asset efficiency.<\/li>\n<\/ul>\n<p>\nFull details of the presentation are outlined in the accompanying attachment.<\/p>\n<p>\n<b>About Palliser Capital<br \/>\n<br \/><\/b>Palliser is an alternative investment manager that applies a value-oriented, event-driven philosophy to investing across a range of distinct yet complementary strategies on a global basis with a focus on situations where positive change and value enhancement can be achieved through thoughtful, constructive, and long-term engagement with companies and across a range of different stakeholder groups.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nProsek Partners<br \/>\n<br \/>Brian Schaffer \/ Kiki Tarkhan \/ Forrest Gitlin<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;t&#111;&#x3a;&#80;&#x72;o&#45;&#x50;&#97;&#x6c;l&#x69;&#x73;&#101;&#x72;&#64;&#x50;r&#111;&#x73;&#101;&#x6b;&#46;&#99;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">&#x50;&#114;o&#x2d;&#80;a&#x6c;&#108;i&#x73;&#101;r&#x40;&#80;r&#x6f;&#115;e&#x6b;&#46;c&#x6f;&#109;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Value Enhancement Plan addresses key drivers of Ajinomoto\u2019s valuation disconnect and sets out a clear, actionable pathway to unlock over 70% upside for shareholders Presentation highlights Ajinomoto as \u201cThe Most Under\u2011Monetised AI Infrastructure Monopoly,\u201d underscoring significant under-appreciated pricing upside of Ajinomoto Build-up Film (\u201cABF\u201d) LONDON&#8211;(BUSINESS WIRE)&#8211;Palliser Capital (\u201cPalliser\u201d), a top 25 shareholder of Ajinomoto Co., &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62870","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Palliser Capital Publishes Value Enhancement Plan for Ajinomoto - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Value Enhancement Plan addresses key drivers of Ajinomoto\u2019s valuation disconnect and sets out a clear, actionable pathway to unlock over 70% upside for shareholders Presentation highlights Ajinomoto as \u201cThe Most Under\u2011Monetised AI Infrastructure Monopoly,\u201d underscoring significant under-appreciated pricing upside of Ajinomoto Build-up Film (\u201cABF\u201d) LONDON&#8211;(BUSINESS WIRE)&#8211;Palliser Capital (\u201cPalliser\u201d), a top 25 shareholder of Ajinomoto Co., ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T08:02:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/1\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto\",\"datePublished\":\"2026-03-31T08:02:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/\"},\"wordCount\":402,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260331226478\\\/en\\\/2761328\\\/1\\\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/\",\"name\":\"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260331226478\\\/en\\\/2761328\\\/1\\\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf\",\"datePublished\":\"2026-03-31T08:02:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260331226478\\\/en\\\/2761328\\\/1\\\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260331226478\\\/en\\\/2761328\\\/1\\\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/","og_locale":"en_US","og_type":"article","og_title":"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto - Pharma Trend","og_description":"Value Enhancement Plan addresses key drivers of Ajinomoto\u2019s valuation disconnect and sets out a clear, actionable pathway to unlock over 70% upside for shareholders Presentation highlights Ajinomoto as \u201cThe Most Under\u2011Monetised AI Infrastructure Monopoly,\u201d underscoring significant under-appreciated pricing upside of Ajinomoto Build-up Film (\u201cABF\u201d) LONDON&#8211;(BUSINESS WIRE)&#8211;Palliser Capital (\u201cPalliser\u201d), a top 25 shareholder of Ajinomoto Co., ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-31T08:02:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/1\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto","datePublished":"2026-03-31T08:02:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/"},"wordCount":402,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/1\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/","url":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/","name":"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/1\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf","datePublished":"2026-03-31T08:02:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/1\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260331226478\/en\/2761328\/1\/EN_Palliser_-_Ajinomoto_Value_Enhancement_Plan_March_2026_-_vSent.pdf"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/palliser-capital-publishes-value-enhancement-plan-for-ajinomoto\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Palliser Capital Publishes Value Enhancement Plan for Ajinomoto"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62870"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62870\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}